Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value? [PDF]
arXiv, 2022 In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value in including an interaction term to model synergism between the two drugs.
arxiv
Employee involvement in and perceptions of campus alcohol and drug abuse prevention programming at UW-Stout [PDF]
, 1999 Plan BNational research has continually shown that college campuses nationwide foster many alcohol and drug use behaviors. It is suggested that faculty and staff may hold several misperceptions in regard to the prevalence and nature of the alcohol and ...
Mishacoff, Natascha L.
core
Equine or porcine synovial fluid as a novel ex vivo model for the study of bacterial free-floating biofilms that form in human joint infections [PDF]
, 2019 Bacterial invasion of synovial joints, as in infectious or septic arthritis, can be difficult to treat in both veterinary and human clinical practice.
Conlon, Brian P. +7 more
core +2 more sources
FoxO1 signaling in B cell malignancies and its therapeutic targeting
FEBS Letters, EarlyView.FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac +3 more
wiley +1 more source
Biocompatible carbon nitride-based light-driven microswimmer propulsion in biological and ionic media with responsive on-demand drug delivery [PDF]
arXiv, 2021 We propose two-dimensional organic poly(heptazine imide) (PHI) carbon nitride microparticles as light-driven microswimmers in various ionic and biological media. Their demonstrated high-speed (15-23 $\mu$m/s) swimming in multi-component ionic solutions with concentrations up to 1 M and without dedicated fuels is unprecedented, overcoming one of the ...
arxiv
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents [PDF]
Biometrical Journal (2018), 2017 Drug combination trials are increasingly common nowadays in clinical research. However, very few methods have been developed to consider toxicity attributions in the dose escalation process. We are motivated by a trial in which the clinician is able to identify certain toxicities that can be attributed to one of the agents.
arxiv +1 more source
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source
Nature Metabolism, 2019 Drug tolerance is an acute defence response preceding a fully drug-resistant state and tumour relapse; however, there are few therapeutic agents targeting drug tolerance in the clinic.
Wen Cai Zhang +11 more
semanticscholar +1 more source
Characterization of HSP90 isoforms in transformed bovine leukocytes infected with Theileria annulata [PDF]
, 2016 HSP90 chaperones are essential regulators of cellular function, as they ensure the appropriate conformation of multiple key client proteins. Four HSP90 isoforms were identified in the protozoan parasite Theileria annulata.
Calder, Ewen D.D. +8 more
core +2 more sources
FEBS Letters, EarlyView.Venom peptides have shown promise in treating pain. Our study uses computer screening to identify a peptide that targets a sodium channel (NaV1.7) linked to chronic pain. We produced the peptide in the laboratory and refined its design, advancing the search for innovative pain therapies.
Gagan Sharma +8 more
wiley +1 more source